title: Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo.
abstract: Resolvin E1 (RvE1) is a potent proresolving mediator of inflammation derived from omega-3 eicosapentaenoic acid that acts locally to stop leukocyte recruitment and promote resolution. RvE1 displays potent counter-regulatory and tissue-protective actions in vitro and in vivo. Periodontal disease is a local inflammatory disease initiated by bacteria characterized by neutrophil-mediated tissue injury followed by development of a chronic immune lesion. In this study, we report the treatment of established periodontitis using RvE1 as a monotherapy in rabbits compared with structurally related lipids PGE(2) and leukotriene B(4). PGE(2) and leukotriene B(4) each enhanced development of periodontitis and worsened the severity of disease. Promotion of resolution of inflammation as a therapeutic target with RvE1 resulted in complete restoration of the local lesion, and reduction in the systemic inflammatory markers C-reactive protein and IL-1beta. This report is the first to show that resolution of inflammation by a naturally occurring endogenous lipid mediator results in complete regeneration of pathologically lost tissues, including bone.
authors.affiliation: Goldman School of Dental Medicine, Department of Periodontology and Oral Biology, Boston University, Boston, MA 02118, USA.
authors.forename: Hatice
authors.initials: H
authors.lastname: Hasturk
authors.forename: Alpdogan
authors.initials: A
authors.lastname: Kantarci
authors.forename: Emilie
authors.initials: E
authors.lastname: Goguet-Surmenian
authors.forename: Amanda
authors.initials: A
authors.lastname: Blackwood
authors.forename: Chris
authors.initials: C
authors.lastname: Andry
authors.forename: Charles N
authors.initials: CN
authors.lastname: Serhan
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Van Dyke
mesh_terms: D016301:Alveolar Bone Loss / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D000818:Animals; D002097:C-Reactive Protein / Q000276:immunology; D002908:Chronic Disease; D015232:Dinoprostone / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives* / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D006706:Homeostasis / Q000276:immunology*; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D018836:Inflammation Mediators / Q000276:immunology*; D053583:Interleukin-1beta / Q000276:immunology; D007975:Leukotriene B4 / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D020556:Neutrophil Infiltration / Q000276:immunology*; D009504:Neutrophils / Q000276:immunology* / Q000473:pathology; D010518:Periodontitis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D011817:Rabbits
chemical_list: D018836:Inflammation Mediators; D053583:Interleukin-1beta; D007975:Leukotriene B4; D002097:C-Reactive Protein; D015118:Eicosapentaenoic Acid; C499823:5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid; D015232:Dinoprostone